Clinical Trial Search

Primary: Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions — -8.4…

Primary: Change in Absolute FVC From Baseline to Post Completion of 8 Weeks of Antibiotic Therapy. — 2.61 liters

Primary: Change in Percent Predicted Absolute Forced Vital Capacity (FVC) in Participants With Pulmonary Sarcoidosis, Comparing Baseline With Performance After Completion of 16…

Primary: Forced Vital Capacity (FVC) — 0.07; -0.07 liters

Primary: Daily Decrease in log10 Transformed Colony-forming Unit (CFU) Counts Per ml Sputum From Baseline (Study Treatment Initiation) to Day 14 — 0.134; 0.096; 0.136; 0.119…

Primary: Bacilli Negative Conversion Rate — 269 participants

Primary: The Steroid Sparing Period — 301; 257 days

Primary: Changes in TB Lesion Sizes Using High Resolution Computed Tomography (HRCT). — 8.11; 10.08; 6.64; 7.24 reader score

Primary: STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76) — 0; 133; 162; 122 Participants

Primary: Change in Inflammation Marker — -43; 7 mg/L

Primary: Number of Participants With 50% Reduction in Corticosteroid Requirement — 3 Participants

Primary: Safety of Escalating Doses of Pravastatin as Assessed by Number of Adverse Events — 8; 4 AEs Grade 3 or Higher

Primary: Number of Participants Without Sarcoidosis Flare (Flare-Free Survival) — 2; 7 Participants

Primary: Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 16 — 2.02; 1.15; -0.15 percent of predicted FVC — p=0.543

Primary: Change Between Baseline and Week 24 in Pulmonary Function as Measured by Spirometry — -1.90; 0.52 Percent Predicted Forced Vital Capacity

Primary: Change in log10 Colony Forming Units (CFU) Per (/) Milliliter (mL) of Direct Respiratory Sputum Samples From Baseline to Day 14 — -0.199; -0.017; -0.092; -0.092…

Primary: Proportion of Patients With Sterile Sputum Cultures — 59; 45 Participants

Primary: Number of Participants With Sputum Culture Conversion in Mycobacteria Growth Indicator Tube (MGIT) at Week 24 — 3; 16 Participants — p==0.002

Primary: The Time to Sputum Culture Conversion at Week 8 (Stage 1) — 51; NA Days — p=0.0034

Primary: The Median Time to Sputum Culture Conversion — 57 Days

Primary: Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 0-14)…

Primary: Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat — 13; 3 Participants

Primary: Karnofsky Performance Status (KPS) Score — 76.67; 76.67 score on a scale — p=1.0

Primary: Percentage of Patients With Clinically Significant Improvement in Visual Acuity — 3 Participants

Primary: Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time…

Primary: Change in Semi-Quantitative Mycobacterial Culture Results From Baseline to Day 84. — 5; 5; 1; 1 Participants — p=0.072

Primary: Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time…

Primary: The Rate of Change in Colony Forming Units (CFUs) Using Non-linear Mixed Effects Modeling of the Serial Sputum Colony Counts (SSCC) Over 8 Weeks of Treatment. — 0.133…

Primary: Change in Percent Predicted FVC From Baseline to 16 Weeks of Treatment — -0.48; 1.02 Percent predicted — p=0.1804

Primary: Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC) — 0.98; 0.98; 0.96; 0.95 Percentage — p=<0.001